Matthew Keller
Stock Analyst at HC Wainwright & Co.
(0.81)
# 4,322
Out of 5,093 analysts
10
Total ratings
22.22%
Success rate
-9.65%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Keller
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SXTP 60 Degrees Pharmaceuticals | Assumes: Buy | $6 | $0.96 | +523.70% | 1 | Nov 14, 2025 | |
| SNSE Sensei Biotherapeutics | Downgrades: Neutral | n/a | $7.97 | - | 1 | Oct 30, 2025 | |
| ACXP Acurx Pharmaceuticals | Reiterates: Buy | $31 | $4.24 | +631.13% | 2 | Sep 30, 2025 | |
| FGEN FibroGen | Reiterates: Buy | $43 | $8.43 | +410.08% | 2 | Sep 24, 2025 | |
| IFRX InflaRx | Assumes: Buy | $6 | $1.06 | +466.04% | 1 | Sep 2, 2025 | |
| GYRE Gyre Therapeutics | Initiates: Buy | $18 | $8.05 | +123.60% | 1 | Aug 26, 2025 | |
| PHIO Phio Pharmaceuticals | Reiterates: Buy | $14 | $1.15 | +1,117.39% | 1 | Aug 15, 2025 | |
| GALT Galectin Therapeutics | Reiterates: Buy | $6 | $5.94 | +1.01% | 1 | Aug 14, 2025 |
60 Degrees Pharmaceuticals
Nov 14, 2025
Assumes: Buy
Price Target: $6
Current: $0.96
Upside: +523.70%
Sensei Biotherapeutics
Oct 30, 2025
Downgrades: Neutral
Price Target: n/a
Current: $7.97
Upside: -
Acurx Pharmaceuticals
Sep 30, 2025
Reiterates: Buy
Price Target: $31
Current: $4.24
Upside: +631.13%
FibroGen
Sep 24, 2025
Reiterates: Buy
Price Target: $43
Current: $8.43
Upside: +410.08%
InflaRx
Sep 2, 2025
Assumes: Buy
Price Target: $6
Current: $1.06
Upside: +466.04%
Gyre Therapeutics
Aug 26, 2025
Initiates: Buy
Price Target: $18
Current: $8.05
Upside: +123.60%
Phio Pharmaceuticals
Aug 15, 2025
Reiterates: Buy
Price Target: $14
Current: $1.15
Upside: +1,117.39%
Galectin Therapeutics
Aug 14, 2025
Reiterates: Buy
Price Target: $6
Current: $5.94
Upside: +1.01%